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AbstrACt 
Introduction Currently, all people with diabetes (PWD) 
aged 12 years and over in the UK are invited for screening 
for diabetic retinopathy (DR) annually. Resources are not 
increasing despite a 5% increase in the numbers of PWD 
nationwide each year. We describe the rationale, design 
and methodology for a randomised controlled trial (RCT) 
evaluating the safety, acceptability and cost-effectiveness 
of personalised variable-interval risk-based screening 
for DR. This is the first randomised trial of personalised 
screening for DR and the largest ophthalmic RCT in the 
UK.
Methods and analysis PWD attending seven 
screening clinics in the Liverpool Diabetic Eye Screening 
Programme were recruited into a single site RCT with 
a 1:1 allocation to individualised risk-based variable-
interval or annual screening intervals. A risk calculation 
engine developed for the trial estimates the probability 
that an individual will develop referable disease (screen 
positive DR) within the next 6, 12 or 24 months using 
demographic, retinopathy and systemic risk factor data 
from primary care and screening programme records. 
Dynamic, secure, real-time data connections have 
been developed. The primary outcome is attendance 
for follow-up screening. We will test for equivalence 
in attendance rates between the two arms. Secondary 
outcomes are rates and severity of DR, visual outcomes, 
cost-effectiveness and health-related quality of life. The 
required sample size was 4460 PWD. Recruitment is 
complete, and the trial is in follow-up.
Ethics and dissemination Ethical approval was obtained 
from National Research Ethics Service Committee North 
West – Preston, reference 14/NW/0034. Results will be 
presented at international meetings and published in 
peer-reviewed journals. This pragmatic RCT will inform 
screening policy in the UK and elsewhere.
trial registration number ISRCTN87561257; Pre-results.
IntroduCtIon
background
Diabetes mellitus (DM) is a life-long condi-
tion associated with the development of 
various macrovascular and microvascular 
complications, including diabetic retinopathy 
(DR) and maculopathy (a subgroup within 
DR). These are progressive conditions of the 
retina and macula, which can lead to visual 
impairment (VI) and blindness. There are an 
strengths and limitations of this study
 ► Our study addresses one of the primary current is-
sues in the field of screening for diabetic retinop-
athy: the safety of extending the interval between 
episodes.
 ► Our study has significant novelty applying a person-
alised approach to a whole population intervention, 
using routinely collected data from primary and sec-
ondary care, a risk calculation engine that allows 
generalisation and evaluated in the first RCT con-
ducted on screening for diabetic retinopathy.
 ► Strengths include the substantial involvement of 
people with diabetes in the design and implemen-
tation, large numbers of participants for tight confi-
dence limits, pragmatic solutions for variable quality 
routine National Health Service data and the inde-
pendent analysis by an accredited clinical trials unit.
 ► The risk calculation engine  has been internally vali-
dated but will require further external validation be-
fore implementation could be considered elsewhere.
 ► The trial only recruits people currently attending 
screening and does not identify the impact for peo-
ple who currently do not attend.
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estimated 3.8 million people with diabetes (PWD) aged 
16 years and over in England,1 of whom almost 1 million 
are undiagnosed. Nearly all people with type 1 diabetes2 
and over 60% with type 2 diabetes3 will develop some 
degree of DR after 20 years of having diabetes.
DR affects people of all ages and is the most common 
cause of blindness in people of working age in most 
developed countries worldwide. In the UK, this position 
has changed. Liew et al4 reviewed the causes of blind-
ness certifications in working age adults in England and 
Wales in 2009–2010 and reported that DR had dropped 
to the second most common cause compared with 10 
years earlier. Tighter control of glycaemia and hyperten-
sion will have contributed to this, but it is probable that 
screening for DR has also played a key role.
The early stages of DR (background and mild pre-pro-
liferative) are asymptomatic and do not require any treat-
ment. Sight-threatening diabetic retinopathy (STDR; an 
umbrella term that encompasses sight-threatening levels 
of retinopathy and maculopathy) requires close moni-
toring by an ophthalmologist, and sometimes treatment, 
to prevent VI.
Treatment (by laser photocoagulation or intravitreal 
injections) aims to stop progression and stabilise retinop-
athy. Treatment cannot always reverse the process once 
vision is lost. Screening is therefore recommended to 
identify STDR at the optimal time-point for treatment. 
Previous studies have shown that screening for DR is a 
highly cost-effective intervention5 6: the higher the take-up 
rates for screening, the higher the cost-effectiveness.7
Annual systematic screening for DR for all PWD aged 
12 years or older was introduced across the UK by 2007. 
A 1-year interval between screening invitations (screen 
interval) was based on expert opinion, rather than direct 
evidence. In 2016, the UK National Screening Committee 
recommended that PWD at low risk of sight loss could be 
screened every 2 years, but this has not yet been adopted. 
This stratified approach was based on evidence from a 
large observational study in one English programme and 
a cost-effectiveness analysis.8 The findings were validated 
in the Welsh, Scottish and Northern Ireland programmes 
and four more English programmes. Stratified screening 
is due to be implemented in Scotland.
Available evidence shows that many people at low risk 
of developing referable DR between annual screening 
appointments could safely be screened less often,9 while 
others are at high risk and might benefit from more 
frequent screening.10 In 1996, Davies et al11 used simu-
lation modelling of published data and concluded that 
biennial screening could be considered where patient 
compliance and screening sensitivities were both high. 
Data on 10-year incidence from the Liverpool Diabetic 
Eye Study—for a population of people with type 2 DM 
and enrolled in a systematic screening programme—
suggested that a 3-yearly screening interval could be 
adopted for PWD with no retinopathy at baseline, but 
yearly or more frequent screening was recommended for 
people with higher grades of retinopathy or insulin use.12 
Similar results were shown for type 1 DM.13 In Sweden, 
biennial screen intervals have been used for some time 
for subjects without retinopathy.14 A study carried out 
in Malmo prospectively followed people with type 2 DM 
and no retinopathy and concluded that it appeared safe 
to adopt 3-year intervals15 as suggested by the Liverpool 
group. However, this group of PWD were compliant (only 
9% did not attend for follow-up) and had a short dura-
tion of diabetes (6±6 years) and good control (glycated 
haemoglobin (HbA1c) 6.4%±1.5% at baseline and 
6.3%±1.3% at 3-year follow-up).
Two studies have looked at stratified screening and 
shown that the risk of progression to STDR is significantly 
higher for those with background DR (BDR) in both eyes 
than those with BDR in only one or in neither eye.16 17 
The first of these two studies suggested that combining 
the results from two consecutive years of photographic 
screening enabled estimation of the risk of future devel-
opment of STDR. People with no DR on two consecutive 
visits were deemed to be low risk.
So why hasn’t an extended interval in screening for 
STDR been more widely adopted? There has been consid-
erable concern about the safety of extending screen inter-
vals and, to date, no randomised controlled trial (RCT) 
has reported.9 The experience of Sweden and Scotland 
is reassuring, but the populations are much smaller and 
generally better engaged. If people receive the impres-
sion that they are at low risk, they may disengage with 
other aspects of diabetes care. Despite encouraging 
findings from our group in 2003, in the absence of the 
required safety data, it appears unwise to recommend 
2-year or 3-year intervals for PWD at low risk without 
further evidence.
rationale for an rCt
With this in mind, we designed an RCT to investigate the 
safety of extending screening intervals in low-risk PWD. 
We included the emerging theories and technologies 
of risk prediction and personalisation to develop a risk-
based variable-interval screening approach and incorpo-
rated an economic evaluation.
In addition to severity of retinopathy, the risk of devel-
opment and progression of DR to a level that requires 
treatment is related to age, gender,1 2 duration of diabetes, 
glycated haemoglobin (HbA1c) levels,18–23 blood pres-
sure,24–26 lipid levels27 and proteinuria.28 If the contri-
bution of each risk factor to overall risk (as well as the 
overall contribution in combination) could be calculated, 
and data on each risk factor were available for individ-
uals, individual risks could be estimated and screening 
frequencies could be tailored to the level of personal 
risk.29
We developed a risk calculation engine (RCE) using a 
longitudinal dataset from our local diabetic population 
to predict the risk of developing STDR and have reported 
confident estimates of the risk of having STDR.30 In 
Iceland, a similar risk algorithm has also been devel-
oped to estimate the risk of development of STDR but 
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based on modelling of historic epidemiological data on 
a limited number of risk factors for DR.31 In the Nether-
lands, a screening model based on patients’ risk has been 
validated in 3319 people with type 2 diabetes as part of 
the Hoorn Study.32 We embedded a patient and public 
involvement (PPI) group in the development of the RCE 
and subsequent design of the trial. There has been scant 
research into people’s understanding of screening and 
their views about introducing variable screening inter-
vals. Yeo et al33 reported that extended intervals may be 
acceptable to the majority of PWD if there was adequate 
evidence to support such a change.33 We found that over 
a series of workshops the PPI volunteers became expert in 
the field and made important design decisions.
We believe that screening for referable DR at intervals 
based on individual risk could be both safe and cost-effec-
tive compared with annual screening. In this paper, we 
report the key features of the design of an RCT designed 
to test this hypothesis.
Funding and ethics approval
The Individualised Screening for Diabetic Retinopathy 
(ISDR) RCT is part of a larger programme of applied 
research funded by a £2.1 million grant from the National 
Institute for Health Research (NIHR) Programme 
Grants for Applied Research programme – reference 
RG-PG-1210–12016. SH is the chief investigator for the 
seven workstream programmes, and DMB is the prin-
cipal investigator for the RCT. The RCT is supported by 
the Clinical Trials Research Centre in Liverpool, which 
provides information systems support, developed elec-
tronic case report files and manage the data. There are 
three trial oversight committees: a trial management 
group, a trial steering committee and the independent 
data and safety monitoring committee. The composition 
and membership of the committees was approved by 
NIHR. The study protocol,34 patient information sheets 
and consent forms have received ethical approval from 
the National Research Ethics Service Committee North 
West – Preston (reference: 14/NW/0034). Recruitment 
to the trial was supported by research staff from Clinical 
Research Network North West Coast, Liverpool Diabetic 
Eye Screening Programme (LDESP) staff and trained 
student volunteers.
trial status
The trial opened to recruitment on the 12 November 
2014. The first patient was randomised on the 19 
November 2014. The trial was closed to enrolment on the 
31 May 2016. The target of 4460 patients was reached. 
The programme grant completes on 30 April 2019.
Patient and public involvement
We have included members of our PPI Group in all stages 
of the design of the trial. Our PPI group consists of seven 
individuals and has met at regular intervals throughout 
the lifetime of the trial. Individuals are active partici-
pants in the programme and trial steering committees, 
programme investigators committee and trial manage-
ment committee. Individuals were involved in the concept 
and development of the research questions, design of the 
trial and the grant application. One patient is a coinves-
tigator and was closely involved in designing the inter-
vention including reviewing the potential burden. The 
group was involved in the choice of risk factors for consid-
eration for the RCE and secondary outcome measures. 
They developed a set of patient-centred outcomes, most 
notably adding VI and need for treatment, which they 
viewed as particularly important to patients. They consid-
ered the chance of missing disease if screen intervals were 
extended and after several structured sessions settled on 
a 2.5% risk as an acceptable limit. They were not involved 
in actual recruitment to the trial, but they visited the 
screening centres and observed recruitment and gave 
constructive comments, which improved the process.
Regarding dissemination of results, these will be sent to 
the participants’ general practitioners. Participants have 
also been advised to let the researcher know if they would 
like a summary of the results themselves.
Participants, interventions and outcomes
Trial design
The ISDR RCT had 1:1 allocation to an indivdualised risk-
based screening recall (6, 12 or 24 months) or annual 
screening (current routine care).
Objectives
The objective of the ISDR RCT is to evaluate the safety, 
acceptability and cost-effectiveness of personalised 
screening in a whole population setting. The main aim is 
to assess the relative safety of variable-interval screening 
as measured by attendance rate. We will test the hypoth-
esis that the difference in attendance rates between the 
two pathways is within an acceptable equivalence margin.
Study setting
This single site trial is being conducted in all seven 
screening clinics in the LDESP, which is part of the English 
National Diabetic Eye Screening Programme (NDESP).
Study population
PWD registered with a GP whose postcode is in the city 
boundaries of Liverpool and attending for screening 
for DR were invited to enter the trial. The inclusion and 
exclusion criteria are given in table 1.
The schematic of the ISDR RCT study design is given 
in figure 1.
data flows
Data flows are shown in figure 2. Data on the participant’s 
retinopathy status feeds automatically from the screening 
software (OptoMize, EMIS health) into the data ware-
house (DW) and then to the randomisation and RCE 
programmes on a daily basis. The ISDR DW automatically 
populates the majority of the fields in the baseline and 
follow-up electronic CRFs (OpenClinica), including data 
that allowed randomisation to occur.
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Primary endpoint
The primary outcome is the attendance rate for follow-up 
screening in the two arms of the study. Non-attendance is 
defined as failure to attend any screening appointments 
within 90 days of the expected follow-up date, irrespective 
of how many appointments they had been sent.
secondary endpoints
 ► Number of cases of STDR detected.
 ► Retinopathy level at screening.
 ► Maculopathy level at screening.
 ► Number of false positive screening episodes.
 ► Number of screening appointments.
 ► Number of diabetes assessment clinic appointments.
 ► Number of other eye appointments for DR.
 ► Visual acuity (log of the minimum angle of resolution 
[logMAR]). 
 ► New VI (≥+0.30 and ≥+0.50 logMAR),
 ► New VI (≥+0.30 and ≥+0.50 logMAR) which, in the 
opinion of an experienced clinician, is due to DR.
 ► Number of missed appointments to screening.
 ► Patient acceptability measures (using a questionnaire 
designed for the RCT).
 ► Quality-adjusted life years (QALYs) estimated using 
EQ-5D-5L and Health Utilities Index Mark 3 (HUI3).
 ► Cost per QALY.
Intervention, assessments and procedures
The ISDR DW is a relational database that stores both 
the data and how the data are related. The Liverpool GPs 
gave permission for their PWD to be directly contacted to 
give permission for the data held in primary care relating 
to their diabetes to be transferred to the DW. The DW was 
established to collate and dynamically link individual risk 
factor data from GP practices, STDR outcome data from the 
DR assessment clinic at St Pauls Eye Unit and the LDESP 
screening software (OptoMize). This central data repository 
was used to develop the locally applicable RCE described 
above using a continuous Markov model.
The RCE was developed using routinely collected primary 
and secondary care data from 11 806 PWD (46 525 screening 
episodes) in the LDESP. A detailed description of the RCE 
has already been published.30 In brief, the final covariates for 
the RCE were selected using a three-step decision process. 
A number of risk factors for developing STDR were identi-
fied in the published literature and in preliminary work in 
Liverpool. These potential covariates were reviewed by the 
clinical team and the PPI group, and potential additional 
covariates were suggested. Potential covariates with a miss-
ingness rate of less than 20% in the DW were identified. 
Then a statistical evaluation of the predictive value of each 
remaining covariate was undertaken. The covariates selected 
were disease state (current retinopathy levels in both eyes); 
age; duration of diabetes; glycated haemoglobin; systolic 
blood pressure; and total cholesterol. The results suggested 
that implementing personalised risk-based intervals would 
reduce the number of screen episodes by 30%.
Our PPI group defined the degree of risk (up to 2.5% 
risk of developing screen positive DR) acceptable to PWD, 
allowing assignment of individuals to screen intervals at 
the time points 6, 12 or 24 months. The choice of these 
intervals was based on a review of the available literature, 
our data and consensus between the PPI and research 
teams. Following each negative screening outcome, indi-
viduals are assigned to the longest recall period up to 24 
months at which their risk estimation would not exceed 
the 2.5% threshold.
Table 1 Inclusion and exclusion criteria in the personalised variable-interval risk-based screening for diabetic retinopathy 
randomised controlled trial
Inclusion criteria Exclusion criteria
Adults, young people and children who are 
aged ≥12 years.
Under age 12 years.
Due to be offered an appointment for retinal 
screening during the recruitment period.
Registered with a participating GP practice. Are not registered with a participating GP practice.
Are included in the study data warehouse (have 
not opted out).
Have opted out from the study data warehouse.
Have no retinopathy or have retinopathy and 
maculopathy less than the definition of screen 
positive diabetic retinopathy.
Have screen positive diabetic eye disease or significant other eye disease 
requiring referral to the HES.
Have gradeable digital retinal images in both 
eyes.
Are ineligible for screening for whatever reason, including having ungradable 
digital retinal images, which includes patients who have only one eye or an 
ungradable eye with no visual potential.
Give their informed consent for participation. Do not give consent for participation in the RCT.
Are not involved in any trial investigating a 
treatment aiming at preventing or modifying the 
development of STDR.
Are involved in any trial investigating a treatment aiming at preventing or 
modifying the development of STDR.
GP, general practitioner; HES, hospital eye service; STDR, sight-threatening diabetic retinopathy.
 o
n
 N
ovem
ber 18, 2019 by guest. Protected by copyright.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2018-025788 on 17 June 2019. Downloaded from 
5Broadbent DM, et al. BMJ Open 2019;9:e025788. doi:10.1136/bmjopen-2018-025788
Open access
Consent
Individuals received a patient information leaflet with 
all the details of the trial with their screening appoint-
ment reminder letter. On attending the screening clinic, 
they were approached by trained researchers to estab-
lish whether they wished to participate in the trial. If 
they expressed an interest, the researcher took written 
informed consent and enrolled them into the trial. If an 
individual subsequently requested to be withdrawn from 
the trial, they reverted to routine care. Reasons for, and 
level of, withdrawal were collected.
randomisation
Randomisation could only be completed once the indi-
vidual’s retinal images had been graded, as it was only 
possible at this point to complete the inclusion and exclu-
sion criteria. PWD who screened positive due to DR, 
other eye disease or ungradable images were therefore 
consented but were not included in the trial.
Eligible PWD were randomly allocated to the person-
alised risk-based screening recall or the usual fixed 
annual interval. Participants were stratified by clinic and 
age (<16 and ≥16 years old). The screening clinics in 
Liverpool had different proportions of PWD in hard to 
reach groups, such as minority ethnic groups, attendance 
rates and social deprivation indices.
After randomisation the RCE was used to generate the 
individual’s recall period in the personalised arm of the 
trial and the data was sent back to the screening software.
Figure 1 Schematic of the ISDR RCT trial design.
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study visits and assessments
At each follow-up visit, PWD randomised to the person-
alised risk-based screening arm have their risk recalcu-
lated and the next recall interval determined accordingly.
Health economics
Table 2 shows the trial intervention diagram.
A health economics questionnaire, incorporating 
the health-related quality of life (QoL) questionnaires 
EQ-5D-5L (an instrument to meaure health state devel-
oped by the EuroQol group)35 and Health Utility Index 
3 (HUI3)36 and a bespoke visit questionnaire,37 was 
completed by the first 868 eligible PWD enrolled into the 
study (a minimum of 700 PWD was required to provide 
sufficient data). The QoL questionnaires are repeated 
at every subsequent follow-up visit for those PWD who 
completed it at baseline.
sample size and planned analyses
The primary aim is to assess the relative safety of person-
alised risk-based interval screening as measured by 
equivalence in attendance rates. The analysis will test 
the hypothesis that the difference in attendance rates 
at the first follow-up between the two pathways is within 
the acceptable range δ =0.05. If the bounds of the 90% 
CI for the difference in attendance rate are found to be 
within the confidence limits ( −δ, δ  (ie, (−0.05 to 0.05)), 
the results would support equivalence.
The estimated minimum number of patients required 
is 3940. With an expected loss to follow-up rate of 6% per 
year due to death and other exclusion from screening 
(note that non-attendance is the primary outcome and 
therefore is not factored here), the target for recruit-
ment (randomised into the trial) was 4460 patients 
(4460*0.94*0.94=3940).
Figure 2 Data flows. In step 1, data for consented participants are requested from OptoMize, passed to the DW and cleaned 
prior to storage. In step 2, data are exchanged between the DW and OptoMize (subjects whose risk needs to be calculated 
are sent to the DW, subjects for whom their risk and therefore recall interval has been calculated is returned to OptoMize 
for appointment letter generation). In step 3, the participants’ risk is calculated (when all the covariates are available); if 
randomisation is required, they are then randomised. The data are then stored in the study database and the DW. All processes 
in steps 1 and 2 involve identifiable data; the processes in step 3 all use pseudanonomised data for security reasons (the trial 
team with access to the trial database do not have a need to see raw identifiers). Step 1 occurs on a bimonthly period, steps 
2 and 3 occur on a daily basis. Under ideal conditions, it takes 3 days for the data to pass through all parts of steps 1 and 2; 
this is due to an air gap (manual transfer) at step 2 between the DW and the National Health Service systems. CRF, case report 
form; DW, data warehouse.
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A secondary aim is to investigate whether personalised 
screening can be considered as non-inferior in detection 
of STDR when compared with annual screening. The 
STDR detection rate predicted for the usual care pathway 
during the 2-year follow-up is approximately 6%, based 
on data from the LDESP. The sample size required to 
address the first question (n=4460 patients randomised 
with 3940 patients retained after 2 years from baseline) 
will permit us to test for non-inferiority in STDR detec-
tion with a maximum allowable reduction of 1.5% of the 
personalised care pathway compared with standard care, 
with 5% significance level and power between 60% and 
65%.
We will undertake subgroup analyses to assess differ-
ences in attendance rates between the two arms for the 
three different retinopathy groups (the risk groups will 
be defined based on the individual baseline estimated 
risk of developing STDR). A logistic mixed-effects model 
that takes into account the patient’s covariate informa-
tion over time (including retinopathy level, HbA1c, 
systolic blood pressure, total cholesterol, disease dura-
tion, and age), and screening clinic (clustered data) will 
be fitted with attendance (yes/no) at the first screening 
visit as the outcome variable. The random effects of the 
model will account for the variability by screening clinic.
Using screening activity data stored in the ISDR DW 
and information collected from the visit questionnaire 
and EQ-5D-5L and HUI3 responses, we will estimate the 
cost per QALY within the study period associated with 
risk-based and annual screening from an NHS perspective 
and where possible incorporate a broader perspective. We 
will present bootstrapped incremental cost-effectiveness 
ratios and cost-effectiveness acceptability curves to char-
acterise the uncertainty associated with our estimates.
We will apply sensitivity analyses to check the sensitivity 
of the results on the assumption that missing data are 
missing at random. Different scenarios for missing data 
mechanisms will be explored.
ConClusIons
This paper describes the design of an RCT to evaluate 
the feasibility, safety, acceptability and cost-effectiveness 
of personalised variable-interval risk-based screening 
compared with fixed annual interval screening. Safety 
will be measured by the effect on attendance rates to 
screening, rates and severity of DR, visual outcomes and 
impact on general diabetes care. As far as we are aware 
this is the only study to investigate the impact of imple-
menting personalised screening for DR in a randomised 
controlled trial.
trial sponsors
 University of Liverpool Research Support Office, 1st floor 
Duncan Building, Daulby Street, Liverpool L69 3GA. Tel: 
0151 706 3702.
 Research and Innovation Department, Royal Liver-
pool and Broadgreen University Hospitals Trust, Prescot 
Street, Liverpool L7 8XP 0151 706 2000. T
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